Embodiments of the invention relate generally to the treatment of inflammatory diseases and disorders and, more particularly, to the treatment of symptoms of inflammatory diseases and disorders using thymoquinone (TQ) alone or in combination with other compounds, including eicosapentaenoic acid (EPA). In one embodiment, the invention provides a pharmaceutical composition suitable for the treatment of at least one symptom of an inflammatory disease or disorder, comprising: an effective amount of thymoquinone； and at least one physiologically-acceptable carrier, wherein an effective amount of thymoquinone is an amount capable of reducing or preventing the at least one symptom of the inflammatory disease or disorder.
